Dave Ricks

“I don't use that one for science actually. It's too, too horrible. Patrick Collison: So which one do you use for science? Dave Ricks: I tend to use either Claude or the XAI one. I find it more terse. And more, the references actually check out more often.”

“We actually have a rule to like never decide in one meeting.”

“We probably have 2000 manmade approved medicines versus natural products or vitamins or other things, and maybe 400 unique mechanisms.”

“The Evandia one, we know well, we work in diabetes, actually caused a policy change, and the policy change was you must rule out cardiovascular risk prior to market entry, and as you may know some conditions like diabetes have a more continuous variable you're…”

“Now, by happy accident, we are all now really pleased with, like, incretins, like our trisepetide to run them because they frequently demonstrate massive benefit. Uncardiovascular. And in some ways, it creates a barrier to entry for the next low-cost Chinese p…”

“There are no generics manufactured in the U.S. Really.”

“There is no requirement For small molecule chemical medicine to show proof of efficacy of any kind. So you can do pretty simple laboratory experiments and absorption experiments in a small number of people.”

“And we probably should pay a little bit more for generics. You sometimes read about injectable generics in particular that run short. That's a more complicated manufacturing process. So if you do it cheaply, you run into more problems. We probably should pay a…”

“We have a study reading out toward the end of this year in chronic knee pain. It's going to work.”

“So we're doing a study with our psoriasis drug, Taltz, and ZepBound. That will read out this fall. And I'm certain we'll show a boost in efficacy with the weight loss.”

“Actually, the number one prescribed form of these medications is Zep-bound self-buy. We sell more than that than our insured business, a new patient starts, and more than all of we go.”

“70% of our spend now is not on linear TV. So most of the advertising is more served up and in your search sequence, and increasingly we're interested in like, generative AI optimization.”

“And there's been studies on this of medical inventions that are not promoted... It's about a sixteen-year path to full adoption. With the medicine promoted, it's half that. We have an internal goal to half that again, to get to four years, to full whatever it …”

“I have a belief that if you're not generating, to generate double digit growth in the sector, you need to invest at 20 to 25% of sales in R&D. That's sort of a good, a positive return R&D stack.”

“We've had a 150 years of that, and I'm the 11th CEO of the company. That's one less than Pope's in that period of time. So that's, it was a special honor, actually, and it's not a lifetime appointment. I can be fired any day, but the first four were family mem…”

“I'd estimate around twenty million take prescription GLP-I's.”

“We're not used to it in the United States. Because we, one, have a, for most people, a pretty good system to subsidize some of the benefit via the insurance markets, so there's not a lot of incentive to go outside the system. That's different for these drugs, …”

“We're doing a deal about every two weeks.”

“So we'll get that drug in three or four years if it works, and I think it could really change some of these terrible mental health conditions.”

“Well, I would be for a system where we don't have nearly as much drug advertising, to be clear.”

“By the way, more than half of our consumer spending to reach consumers is not on TV.”

“I do do it myself. I also do it just to see what the different models are producing about our drugs.”

“It's hard to predict that, but I would say probably a brain disease.”

“I think if you look at human suffering globally, 40% is brain diseases”

“I think last year, five billion with a B went into new venture backed You know, that's what they like to call themselves. And that money is coming not so much from the traditional bio VC world, but from the tech world. Got a lot more to splash around, right?”

“The idea that you're going to throw on, you know, turn a switch on a computer and it's going to think about something and event, you know, the next Prozac. I don't know. I think we're a long way from that day.”

“It's a co-pilot model where the machine can do predictions. Probably now where we see the most value is Eliminating bad ideas that humans don't see, but in hindsight look obvious. So like, cause you can integrate a lot of multi source data and say the probabil…”